OptimizeRx Corporation operates as a digital healthcare technology company. It offers Dynamic Audience Activation Platform, which generates dynamic audiences with predictive analytics through machine learning methods; Micro-Neighborhood Targeting, which creates consumer audiences using a privacy-first process; Profiler, which provides insights into its customers' target consumers; banner messages, including brand messaging, therapeutic support messaging, affordability messaging, limited distribution drug information, and patient support program messaging through healthcare professionals; and media execution solutions, which deliver messages through consumer omnichannel network, including through programmatic display, programmatic connected television/over-the-top, programmatic social media, addressable television, digital out-of-home, programmatic audio, and email/direct mail. The company also offers pharmacy alerts, which flag pharmacies that have prescription medications in stock; and financial messaging solutions, which provide prescribers visibility to branded copay offers for patients directly within electronic health record systems and ePrescribing platforms. The company was founded in 2006 and is headquartered in Waltham, Massachusetts.…
OptimizeRx to Participate in the 15th Annual ROTH Technology Conference
OptimizeRx (NASDAQ: OPRX) is listed on Nasdaq, where its shares trade in USD. It belongs to the Health Information Services industry, part of the Healthcare sector, and reports about 132 employees.
The shares were at 6.700 USD on 20 November 2026, down 64.6% over 52 weeks. Its 52-week range is 4.540 USD to 18.37 USD: the price is 63.5% below the high and 47.6% above the low.
At a market capitalisation of 126.68M USD, it trades at 25.8 times trailing earnings and 6.4 times forward earnings. The median trailing P/E of its 15 largest Health Information Services peers is 39.9, a discount of 35% for OPRX.
OptimizeRx reports return on equity of 4.0%, an operating margin of 12.6% and revenue down 17.1% year over year.
It holds more cash than debt, a net cash position of 9.18M USD. Its Piotroski F-score is 8 out of 9, a strong reading of its financial health. 5 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 11.90 USD is 77.6% above the current price. The next earnings report is expected on 4 March 2027.